Display options
Cite
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429-35doi: 10.2147/IJWH.S40942.
Carlson, M. J., Thiel, K. W., & Leslie, K. K. (2014). Past, present, and future of hormonal therapy in recurrent endometrial cancer. International journal of women's health, 6429-35. https://doi.org/10.2147/IJWH.S40942
Carlson, Matthew J, et al. "Past, present, and future of hormonal therapy in recurrent endometrial cancer." International journal of women's health vol. 6 (2014): 429-35. doi: https://doi.org/10.2147/IJWH.S40942
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014. PMID: 24833920; PMCID: PMC4014387.
Copy Download .nbib Format: NLM
Share it on

Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014.

Past, present, and future of hormonal therapy in recurrent endometrial cancer.

International journal of women's health

Matthew J Carlson, Kristina W Thiel, Kimberly K Leslie

Affiliations

  1. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, USA.

PMID: 24833920 PMCID: PMC4014387 DOI: 10.2147/IJWH.S40942

Abstract

Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven, typically present with a low grade at an early stage, and are of endometrioid histology. These cancers are often cured by surgery, and the rate of recurrence is low. Type II cancers are less differentiated, often appear at a later stage, and are of serous, clear cell, or high grade endometrioid histology. The risk of recurrence in these cancers is much higher than with type I tumors. Isolated pelvic recurrences can be treated with radiation or exenteration, but systemic disease is fatal. It is in these recurrent patients, where prolongation of progression-free survival is the goal, that hormonal therapy can have the greatest benefit. In selected patients, hormonal therapy can be as effective as cytotoxic chemotherapy, without the toxicity and at a much lower cost. Here we review the evidence for treatment of patients suffering from recurrent endometrial cancer with hormonal therapy and explore avenues for the future of hormonal treatment of endometrial cancer. Currently, progesterone is the hormonal treatment of choice in these patients. Other drugs are also used, including selective estrogen receptor modulators, aromatase inhibitors, and gonadotropin-releasing hormone antagonists. Hormonal treatment of recurrent endometrial cancer relies on expression of the hormone receptors, which act as nuclear transcription factors. Tumors that express these receptors are the most sensitive to therapy; it is for this reason that patient selection is vitally important to the successful treatment of recurrent endometrial cancer with hormonal therapy.

Keywords: hormonal therapy; recurrent endometrial cancer

References

  1. Int J Gynecol Cancer. 2004 Jul-Aug;14(4):650-8 - PubMed
  2. Am J Surg Pathol. 2012 Dec;36(12):1771-81 - PubMed
  3. Expert Rev Anticancer Ther. 2003 Feb;3(1):37-47 - PubMed
  4. Gynecol Oncol. 2005 Oct;99(1):135-41 - PubMed
  5. Gynecol Oncol. 2003 Aug;90(2 Pt 2):S40-6 - PubMed
  6. Clin Cancer Res. 2005 Mar 15;11(6):2188-94 - PubMed
  7. Cancer J. 2002 May-Jun;8 Suppl 1:S31-40 - PubMed
  8. Gynecol Oncol. 2007 Aug;106(2):325-33 - PubMed
  9. Nature. 2013 May 2;497(7447):67-73 - PubMed
  10. Mol Cancer Ther. 2005 Jan;4(1):169-75 - PubMed
  11. Gynecol Oncol. 2000 Aug;78(2):212-6 - PubMed
  12. Cancer. 1994 Aug 15;74(4):1303-8 - PubMed
  13. Steroids. 2007 Nov;72(13):829-42 - PubMed
  14. Cancer Genet Cytogenet. 2007 Jun;175(2):107-16 - PubMed
  15. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):964-78 - PubMed
  16. J Clin Oncol. 1999 Jun;17(6):1736-44 - PubMed
  17. Am J Clin Oncol. 2002 Dec;25(6):557-60 - PubMed
  18. Int J Cancer. 2014 Jul 15;135(2):282-94 - PubMed
  19. Discov Med. 2011 Sep;12(64):205-12 - PubMed
  20. Gynecol Oncol. 2000 Apr;77(1):66-72 - PubMed
  21. J Soc Gynecol Investig. 1998 Nov-Dec;5(6):334-8 - PubMed
  22. Gynecol Oncol. 2003 Jul;90(1):64-9 - PubMed
  23. Eur J Cancer. 2005 Mar;41(5):673-5 - PubMed
  24. Gynecol Oncol. 2004 Jan;92(1):4-9 - PubMed
  25. Eur J Cancer. 1999 Feb;35(2):214-8 - PubMed
  26. Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):803-8 - PubMed
  27. J Clin Oncol. 2009 Nov 10;27(32):5331-6 - PubMed
  28. Gynecol Oncol. 2004 Jan;92(1):10-4 - PubMed
  29. Clin Cancer Res. 2009 Oct 1;15(19):6028-34 - PubMed
  30. Gynecol Oncol. 2005 Mar;96(3):741-8 - PubMed
  31. J Clin Oncol. 1996 Feb;14(2):357-61 - PubMed
  32. J Clin Oncol. 2001 Jan 15;19(2):364-7 - PubMed
  33. Gynecol Oncol. 2013 Jun;129(3):486-94 - PubMed
  34. Trends Endocrinol Metab. 2011 Apr;22(4):145-52 - PubMed
  35. Cancer Res. 2001 Jan 1;61(1):97-102 - PubMed
  36. Am J Epidemiol. 2010 Dec 15;172(12):1394-403 - PubMed
  37. Curr Pharm Des. 2014;20(11):1874-80 - PubMed
  38. Expert Opin Investig Drugs. 2000 Dec;9(12):2831-53 - PubMed
  39. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 - PubMed

Publication Types

Grant support